GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

RYTM · Mar 31, 2026

RHYTHM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001628280-26-030549General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

180.44% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-73.50% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

83.81% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

47.66% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

88.09% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-87.11% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

69.41% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

38.43% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History7 statesHistory building

Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/7 normalizedLevel 3 Dec 31, 20250/9 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20260/8 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Increased

Previous: 57.01%
Current: 180.44%
Delta: 123.43%

Cash Generation Decreased

Previous: -60.96%
Current: -73.50%
Delta: -12.54%

Growth Increased

Previous: 45.83%
Current: 83.81%
Delta: 37.98%

Inventory Pressure Increased

Previous: 13.57%
Current: 47.66%
Delta: 34.09%

Margin Decreased

Previous: 89.73%
Current: 88.09%
Delta: -1.63%

Profitability Increased

Previous: -101.19%
Current: -87.11%
Delta: 14.08%

R And D Intensity Decreased

Previous: 88.19%
Current: 69.41%
Delta: -18.77%

Sbc Intensity Increased

Previous: 35.21%
Current: 38.43%
Delta: 3.21%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Has State · RHYTHM PHARMACEUTICALS, INC. →Transitioned To · RYTM Fundamental State →Transitioned To · RYTM BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · RYTM CASH_GENERATION_DECREASED →Transitioned To · RYTM GROWTH_INCREASED →Transitioned To · RYTM INVENTORY_PRESSURE_INCREASED →Transitioned To · RYTM MARGIN_DECREASED →Transitioned To · RYTM PROFITABILITY_INCREASED →Transitioned To · RYTM R_AND_D_INTENSITY_DECREASED →Transitioned To · RYTM SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.